Cooley LLP advised Exscientia on the deal. Exscientia, a clinical-stage pharmatech company, announced its $225 million Series D funding round led by SoftBank Vision Fund 2, which…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
